Liquid Biopsy vs Traditional Tumor Markers for Lung Cancer

Blood tests for lung cancer split into two technological generations. Traditional tumor markers (CEA, CYFRA 21-1, SCC, NSE) — proteins released by cancer cells — have been clinical tools for decades. Modern liquid biopsy (ctDNA) panels — sequencing circulating tumor DNA fragments — became commercially viable around 2015. They answer different questions, have different sensitivities, and cost very differently. This guide explains when each is appropriate.

Two Categories of Blood Tests for Lung Cancer

The category-level differences:

Feature	Traditional tumor markers	Liquid biopsy (ctDNA)
What's measured	Protein concentrations	DNA mutation panels
Sensitivity for early disease	25–40%	25–50%
Sensitivity for advanced disease	70–85%	70–90%
Specificity	Moderate (false positives common)	High (specific mutations rare)
Cost	$50–400 (panel)	$4,500–7,500 (full panel)
Information about mutations	None	Identifies targetable drivers
Tracks treatment response	Yes (slow)	Yes (fast)
Detects emerging resistance	No	Yes

For monitoring known disease, both have roles. For screening, neither is sufficiently sensitive in early-stage disease.

Traditional Tumor Markers (CEA, CYFRA, NSE)

The standard lung cancer marker panel:

• CEA: best for adenocarcinoma; rises in 60–75% of advanced disease
• CYFRA 21-1: best for squamous; rises in 50–70% of advanced disease
• SCC: specific for squamous; less sensitive but more specific
• NSE: small cell lung cancer marker; rises in 60–80% of advanced SCLC
• ProGRP: more specific than NSE for small cell

Combined panel sensitivity (any marker positive in lung cancer): ~85% in advanced disease. Specificity: moderate — many causes of elevation (smoking, COPD, inflammation, other cancers).

Clinical role: monitoring (response to treatment, recurrence detection). NOT screening.

Liquid Biopsy (ctDNA) Pioneers and Tech

ctDNA technology approach:

1. Cancer cells in the tumor die and release DNA fragments into the bloodstream
2. A blood sample is processed to isolate cell-free DNA (cfDNA)
3. The cfDNA is subjected to deep sequencing
4. Mutations specific to cancer (driver mutations, resistance mutations) are identified

Commercial liquid biopsy panels:

• Guardant360 (US): ~70 genes; widely used for solid tumors
• FoundationOne Liquid CDx (US): ~300 genes; tissue-agnostic platform
• Burning Rock OncoLBP60 (China): 60 genes; targeted lung cancer
• Geneseeq lung panel (China): 168 genes; broad solid tumor
• Caris Caris Assure (US): broad panel

These are FDA-approved or comparably regulated in their markets for specific oncology indications.

Sensitivity in Early Stage vs Advanced

The technology limit: ctDNA is shed in proportion to tumor burden. Small early-stage cancers shed minimal ctDNA, often below detection threshold.

Stage	ctDNA detection sensitivity
Stage IA (small, localized)	20–40%
Stage IB-IIA	40–60%
Stage IIB-III	60–80%
Stage IV	80–95%

For symptomatic patients with confirmed advanced disease, liquid biopsy is highly informative. For asymptomatic screening of early-stage disease, sensitivity is too low to be a primary screening test.

Treatment Response Monitoring with ctDNA

A specific scenario where ctDNA shines: monitoring response to targeted therapy.

For an EGFR-mutant lung cancer patient on osimertinib:

1. Baseline ctDNA at treatment start: detects the EGFR mutation (e.g., L858R)
2. Repeat ctDNA at 6 weeks: if the mutation has dropped below detection, treatment is working
3. Repeat at 12 weeks: continued mutation clearance suggests durable response
4. Repeat at progression (rising marker, new imaging): detects resistance mutations (e.g., T790M, C797S) that change next-line treatment

ctDNA detects emerging resistance often weeks before imaging shows progression. This early signal allows treatment adjustment before clinical deterioration.

Traditional tumor markers can also track response (CEA, CYFRA), but they don't identify resistance mutations.

For treatment monitoring with combined modalities, our team can help.

Targetable Mutation Detection

For newly diagnosed advanced non-small cell lung cancer, comprehensive molecular workup is now standard before initiating treatment:

• EGFR mutations: exon 19 deletion, L858R, T790M, exon 20 insertions
• ALK rearrangements
• ROS1 rearrangements
• KRAS G12C
• BRAF V600E
• HER2 mutations
• MET exon 14 skipping
• RET rearrangements
• NTRK fusions

Tissue NGS (next-generation sequencing on a tumor biopsy specimen) is preferred when adequate tissue is available. Liquid biopsy substitutes when:

• Tissue biopsy is impossible or risky
• Tissue specimen is depleted
• Tissue NGS is delayed and treatment cannot wait
• Patient is re-progressing and resistance mutations need rapid detection

Roughly 30% of patients now have both tissue NGS and ctDNA panels at initial workup, used complementarily.

Cost: Markers vs Liquid Biopsy

Test	US (cash)	UK (private)	Mainland China
Single tumor marker	$50–150	£40–120	¥80–200
5-marker lung panel	$200–400	£200–350	¥400–800
Tissue NGS (sequencing panel)	$2,500–4,500	£1,800–3,500	¥6,000–10,000
Liquid biopsy comprehensive	$4,500–7,500	£3,500–5,500	¥8,000–15,000

Liquid biopsy is 20–40× more expensive than a protein marker panel. Insurance coverage:

• US Medicare: covers liquid biopsy in confirmed NSCLC under specific indications
• US commercial: variable; often requires prior authorization
• UK NHS: limited; private pay common
• China public insurance: limited for advanced disease; self-pay typical for international patients

Where to Order Both in China

Top Chinese centers offering comprehensive molecular workup including liquid biopsy:

• Fudan Shanghai Cancer Center — Burning Rock lung panel; integrated with thoracic oncology
• PUMC Beijing — Geneseeq panels; molecular workup standard
• Sun Yat-sen Cancer Center, Guangzhou — full liquid biopsy menu; clinical trial integration
• Shanghai Chest Hospital — high lung cancer volume; routine liquid biopsy
• Cancer Hospital CAMS Beijing — academic and clinical trial focus

Turnaround time for liquid biopsy results: 7–14 days from blood draw to written report. International patients can ship a blood sample (some panels accept FDA-approved blood collection kits) or come in person.

Frequently Asked Questions

Can liquid biopsy replace tissue biopsy?
Not in most newly diagnosed disease. Tissue is preferred for initial diagnosis because it provides histology and full molecular characterization. Liquid biopsy substitutes when tissue is inadequate or for resistance monitoring.

Will my tumor marker rise before liquid biopsy turns positive?
Sometimes the reverse. ctDNA can detect recurrence before tumor markers rise (ctDNA reflects total tumor DNA fragments; markers require sustained cellular activity). The order depends on the specific case.

Does liquid biopsy replace PET-CT?
No. PET-CT shows anatomic location of disease. Liquid biopsy detects mutations in blood without telling you where. They are complementary.

Why don't general physicians order liquid biopsy?
Cost, lack of training in interpretation, and specific indication requirements. It is primarily ordered by medical oncologists for known cancer patients.

Can liquid biopsy detect every cancer type?
The technology is solid-tumor capable but not pan-cancer. Each panel is designed for specific cancer types. Pan-cancer "multi-cancer early detection" panels (Galleri) are emerging but their lung cancer sensitivity remains below LDCT.

Should I get baseline tumor markers even if liquid biopsy is more comprehensive?
Yes — markers are inexpensive and serve as long-term reference points. For monitoring, tracking 2–3 markers over time is straightforward and very cost-effective.

Need Help Booking?

SinoCareLink can pre-book comprehensive tumor marker panels, tissue NGS, or liquid biopsy at a top Chinese cancer center, coordinate oncology consultation, translate reports into English, and arrange airport pickup. Contact us for a free consultation.